CoChat

Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug

Jacobsen, Lisbeth V., Vouis, Jan, Hindsberger, Charlotte, Zdravkovic, Milan · 2011 · The Journal of Clinical Pharmacology

The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.

Abstract

Liraglutide is a once-daily human GLP-1 analog for treatment of type 2 diabetes. Like other GLP-1 analogs, liraglutide delays gastric emptying, which could potentially affect absorption of concomitantly administered oral drugs. This study investigated the effect of liraglutide on the pharmacokinetics of the components of an oral contraceptive (ethinyl estradiol/levonorgestrel). Postmeno-pausal healthy women (n = 21) were included. A single dose of this contraceptive was administered. Blood samples for ethinyl estradiol/levonorgestrel measurements were drawn until 74 hours post dosing of the contraceptive during liraglutide and placebo treatments. The 90% confidence interval (CI) of the ratio of the area under the curve (AUC) (1.06; 90% CI, 0.99-1.13) for ethinyl estradiol (during liraglutide and placebo) was within defined limits, demonstrating equivalence. The 90% CI for the ratio of AUC for levonorgestrel was not fully contained within the limits (1.18; 90% CI, 1.04-1.34) (levonorgestrel AUC was 18% greater with liraglutide vs placebo). However, equivalence was demonstrated for levonorgestrel AUC(0-t) (1.15; 90% CI, 1.06-1.24). Equivalence was not demonstrated for maximum concentration (C(max)); values for ethinyl estradiol and levonorgestrel C(max) were 12% and 13% lower with liraglutide versus placebo, respectively. Both reached C(max) ~1.5 hours later with liraglutide. No clinically relevant reduction in bioavailability of ethinyl estradiol/levonorgestrel occurred.

Overview

Integrity signals

Registry

Crossref · 10.1177/0091270010389471

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 15 references

Research works printed but not linked: 5

  1. Kapitza, 2008, The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol, Diabetes, 57, A593
  2. Malm-Erjefält, 2008, A randomised, doubleblind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects, Diabetes, 57, A130
  3. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site] http:www.ema.europa.eupdfshumanich013595en.pdf
  4. Food and Drug Administration (FDA)., November 1999, Guidance for Industry. In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling
  5. Kothare, 2007, Effects of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women, AAPS J, 9

Cited by

See all 41

Metadata

Authors
Jacobsen, L. V., Vouis, J., Hindsberger, C., & Zdravkovic, M.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • IQVIA (United Kingdom) (GB)
Corresponding author
Jacobsen, Lisbeth V.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2011-12
Volume
51
Issue
12
Pages
1696-1703
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
OpenAlex
W2065045192
Cited by
41
References
16
Citations by year
2026: 8 · 2025: 9 · 2024: 4 · 2023: 1 · 2022: 1 · 2019: 5 · 2018: 1 · 2015: 2 · 2014: 5 · 2012: 4
FWCI
2.83
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1370 d)
Locations
  • The Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, GLP-1 receptor agonists, ethinyl estradiol, levonorgestrel, oral contraceptives, drug-drug interactions, bioavailability, pharmacokinetics, gastric emptying, postmenopausal women, type 2 diabetes
MeSH terms
Liraglutide, Aged, Biological Availability, Contraceptives, Oral, Combined, Double-Blind Method, Drug Combinations, Ethinyl Estradiol, Female, Humans, Hypoglycemic Agents, Middle Aged, Levonorgestrel, Postmenopause, Cross-Over Studies, Area Under Curve, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug. https://app.cochat.ai/papers/10.1177/0091270010389471
The paper
Jacobsen, L. V., Vouis, J., Hindsberger, C., & Zdravkovic, M. (2011). Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive Drug. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270010389471

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.